Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
10.1007/pl00007505 58 SchmiedtR
A 10 mg vial at 250 mcg per dose lasts forty doses, which will outlast the 28 day window on most protocols
Retatrutide is currently in Phase 3 clinical trials, with potential regulatory approval expected around 2026-2027 at the earliest, though timelines can change based on trial outcomes and regulatory review processes
In the OASIS 4 trial, around 7% of participants stopped treatment because of side effects, similar to rates seen with the Wegovy injection
US$ 25.78
US$ 23.70
US$ 27.93
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
